Barriers to use of digitalized healthcare platforms in elderly patients must be overcome before these tools can be used effectively within this patient group. Telemonitoring has shown to be beneficial among elderly patients and may be a viable digitalized healthcare tool for this growing group of patients with cancer. Read More ›

NSCLC patients with advanced KRAS^G12C maintained their quality of life and physical function while receiving sotorasib treatment, with manageable side effects. Read More ›

NGS is becoming increasingly prevalent in cancer treatment. The barriers to NGS testing within the oncology community must be viewed as a priority and must be overcome with help from all stakeholders in the oncologic field. Read More ›

Healthcare personnel’s understanding of patients’ feelings and empathy, along with steps to improve patients’ resilience, are seen as the most important factors in maintaining patients with cancer’s mental state, including maintaining their levels of anxiety and depression. Read More ›

Sotorasib achieved a response rate across all trial subgroups in the recently announced research results of the phase 2 CodeBreaK 100 trial. Read More ›

Patients with NSCLC who are positive for KRAS^G12C have distinct imaging patterns from patients with other NSCLC genetic mutations. Read More ›

Diabetes is associated with increased risk for a number of cancers, including NSCLC. Patients with hyperglycemic NSCLC treated with pembrolizumab show poorer PFS and earlier tumor progression when compared with NSCLC patients with normal blood glucose levels. Read More ›

Finding the right balance between cancer-induced fatigue and immune-oncology–induced fatigue and doing enough exercise to improve general health and better cancer outcomes is a fundamental part of treating patients with cancer. Finding this balance for patients with NSCLC receiving immune-oncology therapy is a key element of overall care for these patients. Read More ›

Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant sotorasib accelerated approval for patients with KRAS^G12C mutation–positive NSCLC. Read More ›

Sotorasib showed encouraging anticancer activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC. Read More ›